• 1
    Fleming DM, Crombic DL. Prevalance of asthma and hayfever in England and Wales. Br Med J 1987; 294: 279283.
  • 2
    Settipane RJ, Hagy GW, Settipane GA. Development of new asthma and allergic rhinitis in a 23-year follow-up of college student. J Allergy Clin Immunol 1991; 87: 232.
  • 3
    Johnston SL, Pattermore PK, Sanderson G., et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. Br Med J 1995; 310: 12251229.
  • 4
    Naclerio RM, Proud D., Togias AG, et al. Inflammatory mediators in late antigen induced rhinitis. N Engl J Med 1985; 313: 6570.
  • 5
    Durham SR, Ying S., Varney VA, et al. Cytokine messenger RNA expression for IL-3, IL-4, IL-5 and GM-CSF in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J Immunol 1992; 148: 23902394.
  • 6
    Rajakulasingam K., Hamid Q., O'Brien F., et al. RANTES in human allergic rhinitis: evidence for synthesis and release after allergen challenge and relationship to tissue eosinophilia. Am J Resp Crit Care Med 1997; 155: 696703.
  • 7
    Ying S., Robinson DS, Meng Q., et al. Enhanced expression of cotaxin and CCR3 mRNA and protein in atopic asthma and their association with airway hyperresponsiveness. Eur J Immunol 1997; 27: 35073516.
  • 8
    Durham SR, Gould HJ, Thienes CP, et al. Expression of ε germ-line transcripts and mRNA for the ε heavy chain of IgE in nasal B cells and the effects of topical corticosteroid. Eur J Immunol 1997; 27: 28992906.
  • 9
    Vamey VA, Jacobson MR, Suddenck RM, et al. Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils and neutrophils. Am Rev Respir Dis 1992; 146: 170176.
  • 10
    Bentley AM, Kay AB, Durham SR. Human late asthmatic responses. In: KayAB, editor. Allergy and allergic diseases. Oxford : Blackwell Science, 1997: 11131130.
  • 11
    Baroody F. Anatomy and physiology. In: NacerioRM, editor. Rhinitis mechanisms and management. Lung biology in health and disease vol. 123. New York : Marcel Dekker Inc., 1998: 122.
  • 12
    Brugman SM, Larsen GC, Henson PM, Honor S., Irvin CG. Increased lower airways responsiveness associated with sinusitis in a rabbit model. Am Rev Respir Dis 1993; 147: 314320.
  • 13
    Bellofiore S., DiMara GU, Martin JG. Changes in upper and lower airway resistance after inhalation of antigen in sensitized rats. Am Rev Respir Dis 1987; 136: 363368.
  • 14
    Rak S., Jacobson MR, Sudderick RM, et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin Exp Allergy 1994; 24: 930939.
  • 15
    Bascom R., Wachs M., Naclerio RM, Pipkorn U., Galli S., Lichtenstein LM. Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid preretreatment. J Allergy Clin Immunol 1988; 81: 580589.
  • 16
    Fokkens WJ, Vroom TM, Rijntes E., Mulder PGH. Fluctuation of the number of CD1a (T6)-positive dendritic cells, presumably Langerhans cells, in the nasal mucosa of patients with isolated grass-pollen allergy before, during and after the grass pollen season. J Allergy Clin Immunol 1989; 84: 3943.
  • 17
    Cameron L., Durham SR, Jacobson MR, et al. Expression of IL-4, Cε RNA and Iε RNA in the nasal mucosa of patients with seasonal rhinitis: effect of topical corticosteroids. J Allergy Clin Immunol 1998; 101: 330336.
  • 18
    Masuyama K., Jacobson MR, Rak S., et al. Topical glucocorticosteroid (fluticasone propionate) inhibits cytokine mRNA expression for interleukin-4 (IL-4) in the nasal mucosa in allergic rhinitis. Immunology 1994; 82: 192199.
  • 19
    Masuyama K., Till SJ, Jacobson MR, et al. Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: effect of topical corticosteroids. J Allergy Clin Immunol 1998; 102: 610617.
  • 20
    Sim TC, Reece LM, Kimberley A., Hilsmeier J., Grant AJ, Alam R. Secretion of chemokines and other cytokines in allergen-induced nasal responses: inhibition by topical steroid treatment. Am J Respir Crit Care Med 1995; 152: 927933.
  • 21
    Welsh PW, Stricker WE, Chu CP, et al. Efficacy of beclomethasone nasal solution, flunisolide and cromolyn in relieving symptoms of ragweed allergy. Mayo Clinic Proc 1987; 62: 125134.
  • 22
    Corren J., Adinoff AD, Buckmeier AD, Irvin CG. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992; 90: 250256.
  • 23
    Foresi A., Pelucchi A., Gherson G., Mastropasqua B., Chiapparino A., Testi R. Once daily intranasal fluticasone priopionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996; 98: 274282.
  • 24
    Pelucchi A., Chiapparino A., Mastropasqua B., Marazzini L., Hernandez A., Foresi A. Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology and bronchial responsiveness to methacholine in allergic rhinitis in response to grass pollens. J Allergy Clin Immunol 1995; 95: 515523.
  • 25
    Watson WTA, Becker AB, Simons FER. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma, effect on lower airway responsiveness. J Allergy Clin Immunol 1993; 91: 97101.
  • 26
    Aubier M., Levy J., Clerici C., Neukirch F., Herman D. Different effects of nasal and bronchial glucocorticosteroid administration on bronchial hyperresponsiveness in patients with allergic rhinitis. Am Rev Respir Dis 1992; 146: 122126.